Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort.

Journal: Gut
Published Date: Jul 30, 2025

Abstract

BACKGROUND: Non-invasive biomarkers with biological rationale are needed for identifying patients with progressive metabolic dysfunction-associated steatohepatitis (MASH).

Authors

  • Vlad Ratziu
    Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
  • Rambabu Surabattula
    Institute of Translational Immunology, Johannes Gutenberg University, Mainz, Germany.
  • Elisabetta Bugianesi
    Medical Sciences, University of Turin, Torino, Italy.
  • Jörn M M Schattenberg
    Saarland University Medical Center Homburg, Germany, Germany.
  • Sudha Myneni
    Medical Sciences, University of Turin, Torino, Italy.
  • Chiara Rosso
    Medical Sciences, University of Turin, Torino, Italy.
  • Angelo Armandi
    Department of Medical Sciences, Division of Gastroenterology and Hepatology, University of Turin, Torino, Italy.
  • Raluca Pais
    Sorbonne Universite, Paris, France.
  • Leila Kara
    ICAN Institute for Cardiometabolism and Nutrition, Paris, France.
  • Frédéric Charlotte
    Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Pathology, Paris, France.
  • Maharajah Ponnaiah
    ICAN Institute for Cardiometabolism and Nutrition, Paris, France.
  • Detlef Schuppan
    Institute of Translational Immunology, Johannes Gutenberg University, Mainz, Germany Detlef.Schuppan@unimedizin-mainz.de.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals